Volume 9, Issue 4 July-Aug 2024, pp: 688-691 www.ijprajournal.com ISSN: 2456-4494

Evaluation of Anti-Parkinson Activity of Lemon Grass

Mrs. Gauri Dhamale. 1*, Mrs Rupali handal 2, Mr. Prashant Bhukan 3, Mrs. Harshali Shelke 4

- ¹Assistant Professor, Department of Pharmaceutical Chemistry, Vishwabharati Academy's College of Pharmacy, Sarola Baddi, Ahmednagar, India
 - ²Assistant Professor, Department of Quality Assurance Technique, Dr. D Y Patil Institute of Pharmaceutical Research and Sciences, Pimpri, Pune
 - ³Assistant Professor, Department of Pharmaceutics, Vishwabharati Academy's College of Pharmacy, Sarola Baddi, Ahmednagar, India
 - ⁴Assistant Professor, Department of Pharmacology, Vishwabharati Academy's College of Pharmacy, Sarola Baddi, Ahmednagar, India

.....

Date of Submission: 20-07-2024 Date of Acceptance: 30-07-2024

ABSTRACT:

The present study was carried out to evaluate antiparkinson activity of ethanolic extract of lemon grass in haloperidol induced experimental animal model by using block method .catalepsy was induced by the intraperitoneal administration of haloperidol at a dose 2 mg/kg body weight by using the 6 rats. all behavioral parameters were assessed by using block method .the cataleptic score was significantly (3.5) found to be reduced with the ethanolic extract of lemon grass .the ethanolic extract of lemon grass is having significant activity in the treatment of Parkinson inhibit haloperidolinduced catalepsy .our result suggest anti-parkinson activity of lemon grass is due to its anti- cataleptic responcesi.e due to the presence of citral (lemonal) constituents.

KEYWORDS: Lemon grass, Anti-Parkinson activity, Haloperidol induced animal model, A.N.O.V.A Test

I. INTRODUCTION:

Parkinson's disease (PD) is a degenerative disorder of the central nervous system. It was first described in 1817 by James Parkinson, a British physician who published a paper on what he called "the shaking palsy." In this paper, he described the major signs and symptoms of the disease that would later bear his name. Research suggests at least 500,000 people in the United States currently have PD, although some estimates are much higher. Society pays an enormous price for PD. The total cost to the nation is estimated to exceed \$6 billion annually. Parkinson's disease belongs to a group of conditions called movement disorders. The four main symptoms are tremor, or trembling in hands, arms, legs, jaw, or head; rigidity, or stiffness of the

limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance. These symptoms usually begin gradually and worsen with time. As they become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. Not everyone with one or more of these symptoms has PD, as the symptoms appear in other diseases as well. PD is both chronic, meaning it persists over a long period of time, and progressive, meaning its symptoms grow worse over time. Unlike measles, you cannot catch Parkinson's disease from someone else. Although some cases of PD are hereditary and can be traced to specific genetic mutations, most cases are sporadic—that is, the disease does not typically run in families. PD likely results from a combination of genetic susceptibility and exposure to one or more environmental factors that trigger the disease. PD is the most common form of parkinsonism, the name for a group of disorders with similar features and symptoms. PD is also called idiopathic PD. The term idiopathic means a disorder for which no cause has been found. While most forms of parkinsonism are idiopathic, there are some cases where the cause is known or suspected or where the symptoms result from another disorder.

II. MATERIAL AND METHODS: Plant material:

The leaves of lemon grass were collected from market. It is cultivated in farms.Lemongrass is a plant that is commonly used in Asian cuisine but which may provide therapeutic and medical benefits. Easily available from any ethnic store, health food store. By using the dried leaves steeped to make a ethanolic extract.

Volume 9, Issue 4 July-Aug 2024, pp: 688-691 www.ijprajournal.com ISSN: 2456-4494

Extraction:

The lemon grass extract is prepared by using solvent ethanol.75 gm powder of lemon grass is soaked in 175 ml ethanol. and allow to soak for five days then remove the liquid extract from the crude drug.

Drying:

The collected ethanolic extract was drying by using rotary evapourator. The ethanolic extract was evapourated under 40° c temperature by using rotary evapourator.

Animals:

The experimentation was carried out by using adult albino rats. Weighing between 150-250 gmwere obtained from P.D.V.V.P.F's college of pharmacy, Vilad Ghat Ahmednagar, Maharashtra. They were maintained at standard housing conditions and fed with commercial diet and provided with water ad labitum during experiment. The institutional animal ethics committee (1670/PO/a/12/CPCSEA) permitted the study.

III. EXPERIMENTATION:

Sr no	animal for testing	Drug	Body wt	Dose	
1	Normal	Distilled water	215 gm	0.1ml	
2	Negative control	haloperidol	170 gm	0.15 ml	
3	Positive control	l dopa+haloperidol	162 gm	20.25mg+0.16ml	
4	Test 1	Test drug+haloeridol	200 gm	200mg+0.2ml	
5	Test 2	Test	150 gm	400mg+0.15	
		drug+haloperidol			
6	Test 3	Test drug	180 gm	600mg+0.18ml	
		+haloperidol			

Albino rats are divided in groups of six each. They were administered haloperidol in -ve control to induce catatonia in positive control the catatonic symptoms are significantly inhibited by levopa. In the test drugs test 2 and 3 no test drug

concentration gives singnificant activity. Chymbopogon Citratus extract 400 mg and 600 mg shows significant effect when compaired with that of standard.



Fig-animal showing 3rd stage of catatonia

Volume 9, Issue 4 July-Aug 2024, pp: 688-691 www.ijprajournal.com ISSN: 2456-4494



Fig-animal showing 4th stage of catatonia

IV. STATICALLY ANALYSIS:

The result are expressed as mean S.E.M. The stastical analysis was performed by analysis of

variance (A.N.O.V.A) by Dunnett'smultipal comparison test.

V. RESULT:

Treatment (Dose in	Duration of Catalepsy in min at							
mg/kg)	0	30	60	90	120	Mean ±SEM		
Normal	00	00	00	00	00	0±0		
Negative control	01	2.5	3.5	3.5	3.5	2.8±0.48		
(Haloperidol) ##								
Positive control	00	0.5	01	01	0.5	0.6±0.18		
(levodopa carbidopa+								
haloperidol) **								
Test 1 C.C Extract	00	2.5	2.5	2.5	0.5	1.8±0.48		
200mg								
Test 2 C.C Extract	00	1.5	1.5	1.5	0.5	1±0.31		
400mg **								
Test 3 C.C Extract	00	01	1.5	01	0.5	0.8±0.25		
800mg **								

n=6,values are express as mean =SEM $**p{<}0.01$ when compaired to negative control , $\#\ p{<}0.01$ when compaired to normal control statistically analysed by one way ANOVA

Application:

1-the chymbopogoncitratus is significantly inhibit the Parkinson disease symptoms.

2-chymbopogon citratus is a natural drug having no any side effects.

3-it is significantly inhibit the Parkinson disease as compare to standard drug.

VI. CONCLUSION:

The chymbopogoncitratus extract 400 mg and 600 mg shows significant effect when compared with that of standard .so the test extract exibit anti-parkinsonactivity, which may be due to the phytochemical constituents present in the extract of chymbopogoncitratus. The constituents present in lemon grass is structurally similar to dopamime hence the lemon grass shows the significant activity to inhibit the parkinson disease.



Volume 9, Issue 4 July-Aug 2024, pp: 688-691 www.ijprajournal.com ISSN: 2456-4494

ACKNOWLEDGEMENT:

The author extremely grateful to Pagar H.J. ph.D Professor and Head, Department of Pharmacology and Author are thankful to the management of P.D.V.V.P.F'S College of pharmacy for providing all the necessary facilities to carry out this work.

REFERENCES:

- [1]. Agarwal SS, ParidhaviM.Herbal Drug Technology, 1stedition.Universities Press (India) Private Limited: Hyderabad.AP, India 2007
- [2]. Fatai KS. Patient consideration in early management of parkinson's disease: focus on extended release pramipexole. Patient Prefer Adherence 6,49-54,2012.
- [3]. Kokate CK, Purohit AP, Gokhle SB. Pharmacognosy,13th edition. NiraliPrakashan: pune,India, 1994.
- [4]. Kulkarni SK.Handbook of Experimental Pharmacology,3rdedition.
 VallabhPrakashan: Delhi, India,2004
- [5]. Satoskar RS, Bhandarkar SD, NirmalaNR.Pharmacology and Pharmacotherapeutics,21st edition. Popular Prakashan: Mumbai, india 2009.
- [6]. Trease GE, Evans WC.Pharmacognosy,16thedition.
 Saunders Elsevie :London,UK,2009
- [7]. Shete RV, Bodhankar SL. Hemidesmusindicus: evalution of its nootropic effect in mice. Int J PharmaBioSci. 3, 1-10, 2010.